Smith Salley Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Smith Salley Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,645	Closed	-$305K	–	164
2015 Q4	$305K	Buy	4,645 +100	+2%	+$6.18K	0.08%	126
2015 Q3	$256K	Hold	4,545	–	–	0.07%	131
2015 Q2	$269K	Sell	4,545 -979	-18%	-$60.4K	0.07%	134
2015 Q1	$344K	Sell	5,524 -3,021	-35%	-$176K	0.09%	129
2014 Q4	$492K	Sell	8,545 -3,423	-29%	-$191K	0.13%	123
2014 Q3	$644K	Sell	11,968 -9,809	-45%	-$520K	0.17%	119
2014 Q2	$1.14M	Buy	+21,777	New	+$1.11M	0.3%	96

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Smith Salley Wealth Management's TEVA Position: Q1 2016 in Review

Smith Salley Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 4,645 shares — an estimated $305K sold.

Smith Salley Wealth Management first reported a position in TEVA in Q2 2014 and held it in 7 quarters. The position peaked at $1.14M in Q2 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Smith Salley Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Smith Salley Wealth Management sold 4,645 Teva Pharmaceuticals shares in Q1 2016, an estimated $305K.
Smith Salley Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 7 quarters.
Smith Salley Wealth Management's Teva Pharmaceuticals position peaked at $1.14M in Q2 2014.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Smith Salley Wealth Management's 13F filing for Q1 2016, filed 10 May 2016.